Aptamer Group pursues a variety of partnerships across the life science ecosystem, aiming to bring our Optimer® platform to enable new solutions for scientific breakthroughs.
Our commitment to innovation and integrity leads to longstanding, valuable partnerships with biopharma companies, academic institutions, manufacturing companies, charitable research organisations, and more.
Optimer® binders enable the selective targeting of biomarkers and tissues with tuneable kinetics and half-life for diverse therapeutic approaches.
We partner with biotherapeutic developers to leverage our platform’s capabilities and develop targeted therapies through:
Cancer Research UK
To develop bifunctional Optimer® therapeutics for the treatment of Chronic Myelomonocytic Leukaemia (CMML)
To develop Optimer®-drug conjugates to target solid tumours
Enabling the pursuit of new biomarkers with assay-compatible binders is breaking down barriers to new and improved diagnostics for global health.
We partner with test developers to advance development with critical tools for a range of assay types, including IHC, LFD, ELISA, and biosensors.
To develop Optimer® binders for the early diagnosis of Alzheimer’s disease
Bioliquid Innovative Genetics
To develop Optimer® to support non-invasive prenatal testing and the diagnosis of placental disease
New solutions are required to increase purity, yield, and cost-efficiencies in bioprocessing and facilitate the next generation of drug targets.
To accelerate and support drug development, we partner with bioprocessing scientists to improve quality control and biomanufacturing across multiple target types.
To develop Optimer® affinity resins for gene therapy manufacturing
Custom Enzyme manufacturer
To develop Optimer® for convenient monitoring of biomanufacturing processes